including the development, production and supply of diagnostic and therapeutic radiopharmaceuticals and radioisotopes.
View moreRelying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
Relying on a global supply chain system, we can consistently to provide stable and reliable radioisotopes. At the same time, we have developed a variety of new nuclide generators, which can effectively alleviate the supply shortage of short half-life radioisotopes in the market.
We are developing a series of molecularly targeted products for the diagnosis and treatment of cancer, that will redefine the next generation of radiopharmaceuticals based on product and technology innovations.
View more
From June 21 to 24, 2025, SNMMI2025, the annual global summit in nuclear medicine and molecular imaging, kicked off in New Orleans, USA. As an innovative participant in China's nuclear medicine industry
View moreTLX101-Px (Pixlumi®) MAA Accepted in Europe
SNMMI Image of the Year: New Immuno-PET Tracer Superior to FDG PET in Predicting PD-L1 Expression in Head and Neck Cancer
SNMMI 2025 Annual Meeting Panorama: In-depth Decoding from the Theranostics Blueprint to the Annual Honor Ceremony
Philochem AG Grants Global Rights of OncoACP3 to RayzeBio in a Deal Worth Up to $1.35 Billion
ASCO 2025: Phase 2 Trial of Re-Treatment with 177Lu-PSMA-617 Molecular Radiotherapy for Metastatic Castration Resistant Prostate Cancer (RE-LuPSMA Trial)
ASCO 2025: Plasma Epigenomic Profiling to Reveal Molecular Correlates of Response and Resistance to 177Lu-PSMA-617 in Metastatic Castration-Resistant Prostate Cancer
